Vasopressin

Baxter Reports First-Quarter 2024 Results

Retrieved on: 
Thursday, May 2, 2024
Medical Supplies, Medical Devices, Health, Pharmaceutical, Optical, Biotechnology, Sale, FDA, Baxter, Pharmacist, Sodium chloride, Food, Growth, LVP, SYR, Novum, Baxter International, Nursing, Patient, EPS, CDT, BPS, GAAP, Food and Drug Administration, Vasopressin

Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2024.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2024.
  • Regardless of the selected path, Baxter currently expects the separation of its Kidney Care business to take place in the second half of 2024.
  • For full-year 2024: Baxter now expects sales growth of approximately 2% on a reported basis and 2% to 3% on a constant currency basis.
  • A webcast of Baxter’s first-quarter 2024 conference call for investors can be accessed live from a link in the Investor Relations section of the company’s website at www.baxter.com beginning at 7:30 a.m. CDT on May 2, 2024.

Baxter Expands Pharmaceuticals Portfolio with New Injectable Products in the U.S.

Retrieved on: 
Thursday, April 11, 2024
Biotechnology, Surgery, Health, Pharmaceutical, Cardiology, FDA, Baxter, USP, Sodium chloride, Injection, Blood pressure, Baxter International, Anesthesia, Patient, Regadenoson, Antimalarial medication, Infection, Hypotension, Catecholamine, Vasopressin, Vancomycin, Pharmaceutical industry

“We are proud to offer important new options for our customers and look forward to continuing to bring new innovations to the market.”

Key Points: 
  • “We are proud to offer important new options for our customers and look forward to continuing to bring new innovations to the market.”
    Product launches within Baxter’s Pharmaceuticals portfolio in the U.S. include the following.
  • For all products, please see full Indications, Important Risk Information and links to full Prescribing Information below.
  • Baxter offers the first and only FDA-approved ready-to-use Norepinephrine in Dextrose, and now provides Norepinephrine in 4 mg/250 mL, 8 mg/250 mL and 16 mg/250 mL strengths.
  • Baxter now offers Vancomycin in 500 mg/100 mL, 750 mg/150 mL, 1 g/200 mL, 1.25 g/250 mL and 1.5 g/300 mL strengths.

Fresenius Kabi Introduces Smart Labels for Diprivan® with Embedded Fully Interoperable +RFID Technology

Retrieved on: 
Monday, October 9, 2023
Data Management, Technology, Manufacturing, Health, General Health, Pharmaceutical, Transport, Health Technology, Software, Logistics, Supply Chain Management, Packaging, Multimedia, Hospital, EPC, RFID, TDS, Vasopressin, Fresenius (company), Propofol, Pharmacist, University, ARC, USP, Auburn University, GS1, Axia, Warehouse

The +RFID labels are now fully compatible with all major RFID kit and tray systems in the U.S.

Key Points: 
  • The +RFID labels are now fully compatible with all major RFID kit and tray systems in the U.S.
  • (Photo: Business Wire)
    The launch expands Fresenius Kabi’s industry-leading +RFID portfolio of fully interoperable labeled medications .
  • Fresenius Kabi is the first pharmaceutical manufacturer to adopt GS1's EPC Tag Data Standard (TDS) to enhance interoperability.
  • Fresenius Kabi is expanding its portfolio of fully compatible +RFID products based on demand from hospitals.

Fresenius Kabi Launches Vasopressin Injection, USP Expanding U.S. Critical Care Portfolio

Retrieved on: 
Wednesday, June 14, 2023
General Health, Pharmaceutical, Health, Cardiology, Blood pressure, Hypersensitivity, Bradycardia, Tachycardia, Indometacin, Use, Fresenius (company), Allergy, Safety, Hyponatremia, Multimedia, USP, Cardiac output, Endo International, Ischemia, Hospital, Patient, Catecholamine, FDA, Diabetes insipidus, Hypotension, Skin, Beta blocker, SIADH, Pharmaceutical industry, Birth control, Vaccine, Dentistry, Vasopressin

Fresenius Kabi announced today the availability in the United States of Vasopressin Injection, USP, a generic equivalent to Vasostrict®.

Key Points: 
  • Fresenius Kabi announced today the availability in the United States of Vasopressin Injection, USP, a generic equivalent to Vasostrict®.
  • Fresenius Kabi Vasopressin Injection, USP is an approved treatment option for adults with vasodilatory shock and is available in a 20 Units per 1 mL Single Dose Vial.
  • Fresenius Kabi produces Vasopressin Injection, USP in the United States where the company has invested nearly $1 billion on an advanced manufacturing and distribution network dedicated to serving U.S. hospitals and health systems.
  • To learn more about how Fresenius Kabi is strengthening America’s supply chain of care, please visit “ More in America .”
    Please see Important Safety Information below.

Global Peptide Therapeutics Market Report 2022: Adoption of New Platforms That Develop Next-Generation Protein or Peptide Therapeutics Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, November 7, 2022
Pharmaceutical, Health, Other Health, Technology, Industry, Ansoff Matrix, Growth, CAGR, Route of administration, Administration, Hormone, Market development, Vasopressin, Geography, Liquid, CMO, USD, SWOT, Glucagon, Investment, Degenerative disease, API, Research, Risk, Strange matter, Fine chemical, Application, Cancer, Inhalable insulin, Calcitonin, Hospital

The Global Peptide Therapeutics Market is segmented based on Synthesis Technology, Drug Class, Route of Administration, API Type, Application, End User, and Geography.

Key Points: 
  • The Global Peptide Therapeutics Market is segmented based on Synthesis Technology, Drug Class, Route of Administration, API Type, Application, End User, and Geography.
  • The report presents a detailed Ansoff matrix analysis for the Global Peptide Therapeutics Market.
  • The analyst analyses the Global Peptide Therapeutics Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • Based on the SWOT analysis conducted on the industry and industry players, the analyst has devised suitable strategies for market growth.

Amneal launches 4 new Generic products, including Vasopressin single-dose

Retrieved on: 
Thursday, August 11, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, FDA, FDA, Vasopressin, Intellectual property, USP, U.S. Securities and Exchange Commission, Risk, Industry, Forward-looking statement, NYSE, Growth, Investment, Amneal Pharmaceuticals, Security (finance), Research, Annual report, COVID-19, Company, Central nervous system, Degenerative disease, Famotidine, Generic, Federation, Ownership, Private Securities Litigation Reform Act, CGT, Weather, Common stock, Birth control, Medical device, Risk management, Clindamycin

Each year, we target 20 to 30 new product launches in generics, and we are on-track to achieving that goal again in 2022.

Key Points: 
  • Each year, we target 20 to 30 new product launches in generics, and we are on-track to achieving that goal again in 2022.
  • Vasopressin injection 1mL is a generic version of the antidiuretic hormone Vasostrict.
  • Famotidine for oral suspension (40 mg/5 mL), an H2 antagonist, is a generic equivalent for Pepcid.
  • This product received Competitive Generic Therapy (CGT) approval designation as Amneal continues to have the highest number of CGT designated products in the industry.

NephroDI Therapeutics Lands Financing to Develop a Treatment for Nephrogenic Diabetes Insipidus, an Orphan Disease

Retrieved on: 
Wednesday, May 12, 2021
Biotechnology, Diabetes, Health, Pharmaceutical, Clinical trials, Medical specialties, Clinical medicine, Branches of biology, Kidney diseases, Rare diseases, Antidiuretics, Thirst, Nephrogenic diabetes insipidus, Diabetes insipidus, NDI, Vasopressin, Kidney disease, NDI-5033, NephroDI Therapeutics, Inc., Xontogeny, LLC, NDI-5033, NEPHRODI THERAPEUTICS, INC., XONTOGENY, LLC

NDI patients produce extremely large amounts of dilute urine resulting from an inability of the kidney to respond to vasopressin.

Key Points: 
  • NDI patients produce extremely large amounts of dilute urine resulting from an inability of the kidney to respond to vasopressin.
  • If hydration is not maintained, it can cause mental retardation and even chronic kidney disease by middle school age.
  • The initial clinical indication for its orally administered lead small molecule is for Nephrogenic Diabetes Insipidus (NDI) in children, a pediatric orphan indication.
  • NephroDI Therapeutics undertakes no obligation to update any forward-looking statements for any reason.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210512005297/en/\n'

Mallinckrodt Announces Data from a Multicenter Post Hoc Analysis of Terlipressin in Patients with Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI) at The Liver Meeting Digital Experience

Retrieved on: 
Monday, November 16, 2020
Antidiuretics, Organ systems, Peptides, Branches of biology, Medical specialties, Vasoconstrictors, Vasopressin, Terlipressin

Terlipressin is an investigational product and its safety and effectiveness have not yet been established by the U.S. Food and Drug Administration.

Key Points: 
  • Terlipressin is an investigational product and its safety and effectiveness have not yet been established by the U.S. Food and Drug Administration.
  • The retrospective chart review study included 250 hospitalized adult patients from 26 centers in theU.K.
  • Terlipressin is a potent vasopressin analogue selective for V1 receptors being investigated for the treatment of HRS-1 in the U.S. andCanada.
  • This release includes forward-looking statements with regard to terlipressin, including its potential impact on patients.

Premier Inc. Data: As COVID-19 Cases Spike, Demand for Drugs Used to Treat Related, Co-Morbid Conditions Also Soars

Retrieved on: 
Thursday, April 30, 2020
Other Health, Research, Managed care, General Health, Pharmaceutical, Data management, Technology, Infectious diseases, Fitness & Nutrition, Science, Other Science, Health, Branches of biology, Drugs, Organ systems, RTT, Peptides, Vasopressin, Amiodarone, Norepinephrine

(NASDAQ: PINC), a leading healthcare improvement company, today released new data finding that as COVID-19 cases peak, so does demand for drugs used to treat cardiovascular conditions and blood clots.

Key Points: 
  • (NASDAQ: PINC), a leading healthcare improvement company, today released new data finding that as COVID-19 cases peak, so does demand for drugs used to treat cardiovascular conditions and blood clots.
  • In hotspots like New York, demand for amiodarone was more than double the national average, soaring by 152 percent.
  • Similarly, Premier data shows two key drugs to manage septic shock, norepinephrine and vasopressin, also experienced higher demand nationally, with orders increasing by 122 percent and 66 percent, respectively.
  • In addition to recommendations Premier has put forward to deal with drugs used to treat COVID-19, Premier recommends additional measures specific to the drugs used for co-morbid conditions, including:
    Manufacturers of these drugs should work proactively with organizations such as Premier to forecast demand and increase capacity/supply to avoid shortages.

Mallinckrodt Completes Rolling Submission of New Drug Application to the U.S. Food and Drug Administration (FDA) for Terlipressin for the Treatment of Patients with Hepatorenal Syndrome Type 1 (HRS-1)

Retrieved on: 
Tuesday, March 17, 2020
Medical specialties, Organ systems, Branches of biology, Peptides, Neuroendocrinology, Neuropeptides, Orgasm, Renal physiology, Vasopressin, American Association for the Study of Liver Diseases, Liver, Terlipressin

The company previously announced the rolling submission, which it initiated in February.

Key Points: 
  • The company previously announced the rolling submission, which it initiated in February.
  • Initial results were presented at The Liver Meeting2019, the annual meeting of the American Association for the Study of Liver Diseases (AASLD).
  • Terlipressin is a potent vasopressin analogue selective for V1 receptors being investigated for the treatment of HRS-1 in the U.S. andCanada.
  • Mallinckrodtuses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information.